HBM Holdings (HKG:2142) expects to post a profit of $62 million to $67 million for the first half of 2026, according to a Friday Hong Kong bourse filing.
The company expects first-half revenue to increase to $120 million to $125 million from $101 million a year earlier.
HBM attributed the expected growth to continued tie-ups with multinational pharmaceutical companies, including its long-term partnership with AstraZeneca and global collaboration with Bristol Myers Squibb.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments